Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-Blind, Placebo- (Double-Dummy) and Active-Controlled, Parallel-Group Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo- (Double-Dummy) and Active-Controlled, Parallel-Group Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MR-107A-02 (Primary) ; Tramadol
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Mylan Specialty

Most Recent Events

  • 08 May 2025 Primary endpoint (Summed Pain Intensity Difference (SPID) for MR-107A-02 versus placebo.) has been met, according to a Viatris media release.
  • 08 May 2025 Results presented in a Viatris Media Release.
  • 08 May 2025 According to a Viatris media release, Full results from both Phase 3 studies will be submitted for presentation at future congresses, including the upcoming PAINWeek 2025 conference in September.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top